Navigation Links
Signal Genetics LLC Announces Update to MyPRS™ Gene Expression Profiling Assay for Multiple Myeloma
Date:7/22/2013

(PRWEB) July 22, 2013

Signal Genetics today announced that it has launched an update to its MyPRS gene expression assay for patients with Multiple Myeloma, which will improve patient prognoses, enable better informed patient care decisions, and ultimately reduce costs.

Every MyPRS test performed now includes an analysis of an additional set of 813-genes within the patient’s genome, which is used to create an individualized ‘Virtual Karyotype’ view of the patient’s disease. This new algorithm is offered in conjunction with the GEP70 risk stratification signature and 7-class molecular subtyping algorithm. The combination of multiple genetic profiles provides the physician with an unparalleled level of personalized information about each patient, and represents the results of decades of research at the University of Arkansas for Medical Sciences (UAMS).

The Virtual Karyotype algorithm, published in Blood (May 24, 2012 vol. 119 no. 21 e148-e150), predicts cytogenetic abnormalities in patients with multiple myeloma using gene expression profiling (GEP) . The accuracy of the method was validated against a range of conventional cytogenetic techniques and was shown to have an accuracy of up to 89 percent. Certain cytogenetic abnormalities, that are a hallmark of Multiple Myeloma, are commonly used as clinical parameters for determining the disease stage and help guide therapy decisions for patients. The Virtual Karyotype algorithm, now included in MyPRS, was designed to be an alternative to conventional methods which can be time consuming, expensive, subjective and often fail due to the difficulties encountered when attempting to culture myeloma cells.

Sam Riccitelli, President and CEO of Signal Genetics said, “We are thrilled that our ongoing relationship with UAMS allows us to bring new developments in the genetic understanding of Multiple Myeloma to physicians and patients throughout the country. The addition of the Virtual Karyotype signature to our MyPRS assay is a major advancement in expanding the already proven clinical utility of GEP for patients with myeloma and should encourage even more physicians to incorporate the test into routine care.”

About MyPRS
MyPRS, developed by UAMS, has been marketed by Signal Genetics since 2011. The multi-gene test, performed on bone marrow aspirate material, has been incorporated into the routine management of patients diagnosed with Multiple Myeloma in numerous treatment centers across the country. MyPRS™ can be used at the time of initial myeloma diagnosis or if the patient has experienced a relapse of their disease.

About Signal Genetics
Signal Genetics LLC is a privately held molecular diagnostic company based in New York, NY and Little Rock, AR focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. For more information, visit https://www.signalgenetics.com or email info(at)signalgenetics(dot)com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10944110.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Signal-Health Develops Easy Checklist to Identify Possible Sweating Issues in Horses
2. Researchers identify signals that direct the immune system to reject a transplanted organ
3. Laser-like photons signal major step towards quantum Internet
4. Physicists skirt thermal vibration, transfer optical signal via mechanical oscillator
5. Needle beam could eliminate signal loss in on-chip optics
6. Todays Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma
7. GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research
8. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
9. Epigenetics: Changing the Way We Think about DNA
10. Research and Markets: Cytogenetics - Technologies, Markets and Companies - 2013
11. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... (NASDAQ: NBIX ) today announced its financial results for the ... --> --> For the fourth quarter of 2015, ... loss per share, compared to a net loss of $19.4 million, ... For the year ended December 31, 2015, the Company reported a ... compared to a net loss of $60.5 million, or $0.81 loss ...
(Date:2/11/2016)... -- Spectra BioPharma Selling Solutions (Spectra) is a new ... the experience, expertise, operational delivery and customer focus ... Created in concert with industry leading commercial experts, ... tactical needs of its clients by providing value-based ... and non-personal promotion. --> ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... new stem cell treatment clinic in Quito, Ecuador. The new facility will provide ... applications to patients from around the world. , The new GSCG clinic ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
Breaking Biology News(10 mins):